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Working capacity is increased following recombinant human erythro-
poietin treatment. To investigate the effect of partial correction of
anemia in patients maintained by chronic intermittent hemodialysis on
aerobic and anaerobic working capacity, eight patients underwent a
bicycle spiro-ergometry before and after treatment with recombinant
human erythropoietin (r-HuEPO). The initial mean (± SD) hemoglobin
value was 5.9 mgldl 0.61 and increased during treatment to 10.9
0.59 mg/dl, P < 0.0001). This partial correction of anemia resulted in a
significant increase of both oxygen uptake at the anaerobic threshold
and peak peripheral oxygen uptake at subjective exhaustion (P < 0.01
and P < 0.0002, respectively). The increase in oxygen uptake corre-
sponded to significant increases in Watts, both at the anaerobic thresh-
old and at maximum workload (P < 0.02 and P < 0.0004). These data
show that partial correction of renal anemia results in a significant
increase of both exercise capacity and maximum work.
Anemia is an almost invariable feature of chronic renal failure
and its severity appears to be correlated with the degree of renal
insufficiency [11. Recently, Winearis et al [2] and Eschbach et a!
[3] were able to demonstrate for the first time the efficacy of
recombinant human erythropoietin (r-HuEPO), which now
promises to be an effective treatment for the anemia of end-
stage renal failure [4, 51. These studies, together with previous
experimental evidence [6] indicate that erythropoietin defi-
ciency plays a major pathogenetic role in this type of anemia.
Little, however, is known about the consequences of raising
hemoglobin concentrations by r-HuEPO administration in dial-
ysis patients. The effects observed so far point to improved well
being of the patients [2—51, which is certainly a desirable effect
but would not necessarily justify general use of r-HuEPO.
Moreover, there may be deleterious effects of raising hemato-
crit and blood viscosity, so that the optimum use of r-HuEPO
therapy in dialysis patients remains to be established.
From a theoretical point of view, any increase of hemoglobin
values should result in improved peripheral oxygen availability
and thus enhanced exercise capabilities. Aerobic exercise ca-
pacity, a good measure of working ability in every day life, has
been shown to be correlated to hemoglobin levels in patients on
chronic hemodialysis, and is grossly impaired in these anemic
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patients when compared to expected values [7]; this contributes
to the poor rehabilitation of some patients on chronic dialysis
treatment.
We describe here the effects of partial correction of anemia
on parameters of exercise capacity in patients on chronic
hemodialysis.
Methods
Eight patients (4 male, 4 female) on chronic intermittent
hemodialysis were studied. Their mean age was 35.5 years (19
to 48 years) and mean time on dialysis was 62 months (44 to 118
months).
At the beginning of the study four patients were on antihy-
pertensive treatment, two were normotensive and two were
hypotensive. Seven patients were on acetate, one on bicarbon-
ate hemodialysis and two patients were treated by hemodia-
filtration. The individual procedure time was calculated using a
computer-assisted urea kinetic modeling system [8]. Pre-dialy-
sis blood urea nitrogen levels were kept under 80 mgldl after a
"long" dialysis interval. This therapeutic regimen was un-
changed during the study period.
All patients were dependent on regular blood transfusions, to
maintain hemoglobin levels greater than 6 g/dl. The number of
transfusions administered during their time on dialysis varied
from 8 to 242 units (mean 77 units). The hemoglobin levels
immediately before the first r-HuEPO administration were 6
g/dl. r-HuEPO was given intravenously at the end of each
hemodialysis session, starting at a dose of 100 U/kg for three
weeks. If the hemoglobin values of the third week were below,
equal or not higher than 5% of the initial value, the r-HuEPO
dose was increased by 25 U/kg/dose. Further dose increments
were performed in the same manner at three week intervals.
The target hemoglobin value was 10 g/dl.
Exercise testing was performed on a bicycle ergometer.
Because of the expected low working capacities, the initial
workload was 25 Watts and was increased stepwise by only 10
Watts each level of work, being maintained for one minute. One
minute stages were used as it was the aim of the study to
determine oxygen consumption at various workloads and not
necessarily to reach steady state conditions during exercise.
Criteria for termination of the exercise test were the same as
used for standard cardiac ergometry. Cardiac exercise limit was
defined as heart rate = 220 — age, maximum mandatory
ventilation was calculated as 35 x FEV 1. However, all patients
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stopped exercise because of general fatigue or leg pain before
an objective criterium for exercise cessation occurred.
Anaerobic threshold was determined as described by Was-
serman et al 191 as a non-linear increase in minute ventilation,
non-linear increase in CO2 production and an increase in end
tidal 02 without a corresponding decrease in end tidal CO2.
All determinations of gas concentrations and volumes were
done on-line during exercise testing using a microprocessor
controlled system (Sensormedics Horizon System IV, Sensor-
medics, Anaheim, California, USA). This integrated system
provides rapid gas analysis and data storage for measuring gas
exchange [10].
All patients were studied at two different hemoglobin levels.
The first test was performed shortly before initiation of r-
HuEPO treatment at a mean 5D hemoglobin concentration of
5.9 g/dl 0.61, and immediately after the target hemoglobin of
10 g% had been exceeded at three hemoglobin determinations at
the beginning of three consecutive hemodialysis procedures.
This resulted in a medium hemoglobin value of 10.9 g/dl 0.59
at the time of the second exercise test.
Statistical analysis was done using Student's t-test for paired
data.
Results
All patients showed a significant increase of hemoglobin
values (from 5.9 0,61 g/dl to 10.9 0,59 g/dl, P < 0.001),
erythrocytes (from 1.85 0.12 to 3.36 0.36 /pl, P c 0.001)
and hematocrit (from 17.13 1.28 to 33.3 2.74%,P<0.OOl).
Although all of the patients qualified as responders to r-HuEPO
the individual time course and dosage requirements varied
considerably. One patient needed an r-HuEPO dosage increase
up to 200 U/kg/dose; the target hemoglobin of 10 g/dl was
reached within 8.9 weeks (from 6 to 16 weeks). The effects of
r-HuEPO therapy on biochemical values, other hematological
parameters and blood pressure are summarized elsewhere [11].
In brief: there were no significant changes of serum BUN,
creatinine and potassium, and no significant changes of serum
BUN, creatinine and potassium, and no significant changes in
platelet or leucocyte counts. Four patients needed an increase
of their antihypertensive therapy concomitant to the increase of
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Fig. 2. Peak oxygen consumption (mi/mm/kg) at subjective exhaustion
before and after partial correction of anemia.
hemoglobin levels; at the time of the examination, however,
blood pressure was within the normal range in all patients. It
should be emphasized that antihypertensive drugs known to
affect oxygen consumption, like beta blocking agents, were
avoided throughout the study period.
Before treatment anaerobic threshold was reached at a mean
oxygen consumption of 13.7 2.05 ml/kgfmin. There was a
significant increase in oxygen consumption at anaerobic thresh-
old after treatment to 19.1 mI/kg/mm 3.4, P c 0.01 (Fig. 1).
Mean peak peripheral oxygen consumption (VO2P) increased
significantly from 16.0 3.4 to 23.2 8.2 mI/kg/mm, P C 0.02
(Fig. 2). However, the unexpected high ratio of VO2AT/VO2P
once more expresses the high personal input in the determina-
tion of exhaustion, as usually one would expect a low ratio in
sedentary patients and therefore the high ratio is mostly ex-
plained by an early cessation of exercise by the patient. The
work load, where anaerobic threshold or VO2P were reached,
also showed significant increases (from 70 16.9 Watts to 106.9
17.3 Watts, P c 0.0002 for anaerobic threshold, and from
91.3 28.3 Watts to 121.9 33.3 Watts for VO2P, P C 0.0004,
respectively) (Figs. 3 and 4).
Heart rate as a parameter of cardiac function was signifi-
cantly lower in the resting state after r-HuEPO therapy (78.4
11.3 vs. 72.8 12.1; P <0.02), but was similar at the anaerobic
threshold (128.7 16.9 vs. 126.3 12.7; NS) and at the end of
exercise (137 23.3 vs. 138 21.3; NS) at the first and second
exercise testing, respectively. Blood pressure did not change
significantly (from 127/70 to 135/80; NS)
Termination of exercise at the maximum work load was
caused by leg pain or general fatigue in all tests. No exercise
test had to be terminated because of hypertension, excessive
heart rate increase or dyspnoea.
Discussion
Our results demonstrate for the first time an improvement of
exercise capacity in dialysis patients after treatment of anemia
with human recombinant erythropoietin. In these sedentary
patients who had undergone no physical exercise training
during the period of r-HuEPO treatment, this increase is
20
10
E
I—C
a
>
Pre-anemia Post-anemia
Fig. 1. Oxygen consumption (mi/mm/kg) at the anaerobic threshold
(AT) before and after partial correction of anemia.
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Pre-anemia Post-anemia
Fig. 3. Workload level (Watts) reached at anaerobic threshold (AT)
before and after partial correction of anemia.
attributable only to the increase in hemoglobin levels and thus
an enhanced oxygen supply to the periphery.
The data presented here confirm previous findings that exer-
cise capacity in patients on chronic hemodialysis is usually less
than 50% of expected values for individuals of the same age and
sex when VO2P is used as parameter of exercise capacity [12].
Several pathogenetic factors seem to contribute to reduced
exercise capacity, the one of major importance being reduced
peripheral oxygen availability due to decreased hemoglobin
levels [7]. The decreased VO2P, however, does not reflect the
limitation in working ability during normal daily life as it reflects
only the limitation in peak exercise ability. Most of the usual
work, however, is endurance work and is performed totally
aerobically in order to avoid acidosis and accompanying fa-
tigue. The determination of the anaerobic threshold therefore
provides substantial evidence for the exercise limitation in
normal every day life, which concerns the patient more than
any inability to perform strenuous exercise. Another advantage
of determination of the anaerobic threshold is its objectivity as
a measure of exercise capacity. In contrast, determination of
VO2P, which requires exercise to exhaustion in the tested
individual is influenced by a variety of factors, and is therefore
much less accurate [13].
The increase of V02 both at the anaerobic threshold and at
maximum exercise was paralleled by increased workload levels
attained during bicycle ergometry. The average work load level,
at which the anaerobic threshold was reached increased from 70
to 106 Watts. An anaerobic threshold of 70 Watts indicates a
very restricted exercise capacity with inability to perform
routine housework over a sustained period, whereas the ability
to perform an exercise of 106 Watts aerobically allows full
physical rehabilitation with regard to every day life. As can be
seen in Figure 4, the Watt increase at subjective exhaustion was
much more uniform than the increase in VO2P. Furthermore,
the increase of VO2AT seems to be less impressive than the
increase of Watt AT or Watt max. One possible explanation
could be a change in efficiency at work, as even small increases
of aerobic metabolism will enhance exercise capacity consider-
ably; an increase in aerobic glycolysis is accompanied by a
much greater ATP gain/mo! 02 than anaerobic glycolysis.
Pre-anemia Post-anemia
Fig. 4. Maximum workload level (Watts) reached before and after
partial correction of anemia.
Until now an increase of exercise capacity in hemodialysis
patients, usually measured in terms of increases in VO2P, could
only be achieved by prolonged and continuous exercise training
[14]. However, it is noteworthy that in these studies the
increase in VO2P was accompanied by an increase in red blood
cell count, indicating the critical effect of decreased peripheral
oxygen content on exercise capacity.
The individual change in peripheral oxygen uptake during
exercise in response to partial correction of anemia was vari-
able. In two patients the increase was minimal or absent. This
might well be due to the fact that peripheral oxygen uptake is
not only a function of peripheral oxygen availability, particu-
larly if the availability of oxygen changes within a relatively
short period of time. An increased availability of oxygen in
muscle results in biochemical adaptions favoring aerobic me-
tabolism within the mitochondria. This adaption, however, is a
function of the duration and intensity of the increased oxygen
availability [13]. It is likely that those patients who did not
respond within the study period would improve if the increase
in hemoglobin levels were to be sustained. Serial determina-
tions of exercise capacity in patients in whom these more
appropriate hemoglobin levels are maintained by r-HuEPO will
help to clarify this question.
In conclusion, our results indicate that the increase of hemo-
globin levels in patients on chronic intermittent hemodialysis,
who are treated with r-HuEPO, results in a significant increase
in both aerobic and anaerobic working capacity. This may lead
to better rehabilitation of patients on chronic hemodialysis and
provide a safe and effective method for improvement in their
quality of life.
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